ALS Therapy to launch phase II trial of TDI 132

Wednesday, February 15, 2012 04:03 PM

The ALS Therapy Development Institute, a nonprofit biotech, will be launching a phase II clinical trial on TDI 132 (fingolimod)—currently used as treatment for multiple sclerosis—as a potential treatment for ALS (Lou Gehrig's disease). 

The primary purpose of this phase II clinical trial will be to determine the safety and tolerability of TDI 132 (fingolimod/Gilenya) in people living with ALS today. The study will provide important information on dosing and safety for a subsequent efficacy study.

"We hope to learn from this study whether or not TDI 132 is safe to test in people living with ALS.  Participants will be evaluated over a month-long exposure to the drug, and we'll be monitoring their response closely," said Merit Cudkowicz, M.D., director of the neurology clinical trials unit at Massachusetts General Hospital and one of the principal investigators.

ALS Therapy researchers first began preclinical testing TDI 132 in 2011 for its ability to block certain immune cells from entering the central nervous system where they can cause activities that result in damage to motor neurons.  The institute has confirmed that TDI 132 significantly alters the trafficking of these immune cells through the bloodstream, resulting in fewer of them infiltrating into and damaging the nervous system. 

Further experiments at ALS Therapy showed treatment with TDI 132 resulted in positive outcomes on several disease measures in preclinical studies in the SOD1 mouse model.  A key partner of ALS Therapy, the Muscular Dystrophy Association, provided significant funding for some of that preclinical work, as did numerous other private donors.

ALS Therapy will be working with the Northeast ALS Consortium (NEALS) to assist with clinical trial design and to oversee the execution of the clinical trial.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs